Signaling through the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) axis is responsible for aerobic glycolysis mediated by glucose transporter in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma

Journal of Biological Chemistry

Volumn 290, Issue 28, 2015, Pages 17495-17504

  Makinoshima, Hideki ^a   Takita, Masahiro ^a,b   Saruwatari, Koichi ^c   Umemura, Shigeki ^c   Obata, Yuuki ^d   Ishii, Genichiro ^c   Matsumoto, Shingo ^a,c   Sugiyama, Eri ^c   Ochiai, Atsushi ^c   Abe, Ryo ^d   Goto, Koichi ^c   Esumi, Hiroyasu ^d   Tsuchihara, Katsuya ^a,b  

^a NATIONAL CANCER CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOCHEMISTRY; BIOLOGICAL ORGANS; CELL CULTURE; CELL PROLIFERATION; CELLS; CYTOLOGY; GENE EXPRESSION; GLUCOSE; GROWTH KINETICS; METABOLISM; PATHOLOGY; SIGNALING;

EPIDERMAL GROWTH FACTOR RECEPTORS; EXTRACELLULAR ACIDIFICATIONS; GLUCOSE TRANSPORTER-1; GLUCOSE TRANSPORTERS; MEMBRANE LOCALIZATION; PENTOSE PHOSPHATE PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; PYRIMIDINE BIOSYNTHESIS;

CELL SIGNALING;

DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEDATOLISIB; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 1; HEXOKINASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OSIMERTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SELUMETINIB; EGFR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; SLC2A1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ACIDIFICATION; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ARTICLE; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IC50; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; METABOLOMICS; MUTANT; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; GENETICS; GLYCOLYSIS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTO ONCOGENE; TUMOR CELL LINE;

MAMMALIA;

ADENOCARCINOMA; AEROBIOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, ERBB-1; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; LACTIC ACID; LUNG NEOPLASMS; METABOLOMICS; MUTATION; PENTOSE PHOSPHATE PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84940055374     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.660498     Document Type: Article

References (52)

1. Tsuchihara, K. (2013) RET-targeting molecular stratified non-small-cell lung cancers. Transl. Lung Cancer Res. 2, 463-465
2. Umemura, S., Tsuchihara, K., and Goto, K. (2015) Genomic profiling of small-cell lung cancer: the era of targeted therapies. Jpn. J. Clin. Oncol. 45, 513-519
3. Gainor, J. F., and Shaw, A. T. (2013) Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 18, 865-875
4. Hallberg, B., and Palmer, R. H. (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer 13, 685-700
5. Filipits, M. (2014) New developments in the treatment of squamous cell lung cancer. Curr. Opin. Oncol. 26, 152-158
6. Stella, G. M., Luisetti, M., Pozzi, E., and Comoglio, P. M. (2013) Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir. Med. 1, 251-261
7. Suzuki, A., Mimaki, S., Yamane, Y., Kawase, A., Matsushima, K., Suzuki, M., Goto, K., Sugano, S., Esumi, H., Suzuki, Y., and Tsuchihara, K. (2013) Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts. PLoS ONE 8, e73484
8. Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., and Settleman, J. (2005) Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 419-426
9. Camp, E. R., Summy, J., Bauer, T. W., Liu, W., Gallick, G. E., and Ellis, L. M. (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11, 397-405
10. Pao, W., and Chmielecki, J. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774
11. Makinoshima, H., Takita, M., Matsumoto, S., Yagishita, A., Owada, S., Esumi, H., and Tsuchihara, K. (2014) Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J. Biol. Chem. 289, 20813-20823
12. Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95
13. Levine, A. J., and Puzio-Kuter, A. M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344
14. Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A. K., Kapoor, A., Yao, W., Brunetto, E., Kang, Y., Yuan, M., Asara, J. M., Wang, Y. A., Heffernan, T. P., Kimmelman, A. C., Wang, H., Fleming, J. B., Cantley, L. C., DePinho, R. A., and Draetta, G. F. (2014) Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628-632
15. Boroughs, L. K., and DeBerardinis, R. J. (2015) Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17, 351-359
16. Lunt, S. Y., and Vander Heiden, M. G. (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464
17. Soga, T. (2013) Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 104, 275-281
18. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033
19. Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J. T., Wu, J., Solow-Cordero, D. E., Bonnet, M., Flanagan, J. U., Bouley, D. M., Graves, E. E., Denny, W. A., Hay, M. P., and Giaccia, A. J. (2011) Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med. 3, 94ra70
20. Lopez-Serra, P., Marcilla, M., Villanueva, A., Ramos-Fernandez, A., Palau, A., Leal, L., Wahi, J. E., Setien-Baranda, F., Szczesna, K., Moutinho, C., Martinez-Cardus, A., Heyn, H., Sandoval, J., Puertas, S., Vidal, A., Sanjuan, X., Martinez-Balibrea, E., Viñals, F., Perales, J. C., Bramsem, J. B., Ørntoft, T. F., Andersen, C. L., Tabernero, J., McDermott, U., Boxer, M. B., Vander Heiden, M. G., Albar, J. P., and Esteller, M. (2014) A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat. Commun. 5, 3608
21. Macheda, M. L., Rogers, S., and Best, J. D. (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654-662
22. Chen, L. Q., Cheung, L. S., Feng, L., Tanner, W., and Frommer, W. B. (2015) Transport of Sugars. Annu. Rev. Biochem. 84, 865-894
23. Szablewski, L. (2013) Expression of glucose transporters in cancers. Biochim. Biophys. Acta 1835, 164-169
24. Weihua, Z., Tsan, R., Huang, W. C., Wu, Q., Chiu, C. H., Fidler, I. J., and Hung, M. C. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393
25. Ohashi, Y., Hirayama, A., Ishikawa, T., Nakamura, S., Shimizu, K., Ueno, Y., Tomita, M., and Soga, T. (2008) Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol. Biosyst. 4, 135-147
26. Ooga, T., Sato, H., Nagashima, A., Sasaki, K., Tomita, M., Soga, T., and Ohashi, Y. (2011) Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol. Biosyst. 7, 1217-1223
27. Cross, D. A., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R., Ward, R. A., Mellor, M. J., Hughes, G., Rahi, A., Jacobs, V. N., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R., Klinowska, T., Richmond, G. H., Cantarini, M., Kim, D. W., Ranson, M. R., and Pao, W. (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046-1061
28. Qu, Y., Wu, X., Yin, Y., Yang, Y., Ma, D., and Li, H. (2014) Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J. Exp. Clin. Cancer Res. 33, 52
29. D'Amato, V., Rosa, R., D'Amato, C., Formisano, L., Marciano, R., Nappi, L., Raimondo, L., Di Mauro, C., Servetto, A., Fusciello, C., Veneziani, B. M., De Placido, S., and Bianco, R. (2014) The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br. J. Cancer 110, 2887-2895
30. Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., Zimmerman, L. J., Liebler, D. C., Slebos, R. J., Lorkiewicz, P. K., Higashi, R. M., Fan, T. W., and Dang, C. V. (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15, 110-121
31. Sellers, K., Fox, M. P., Bousamra, M., 2nd, Slone, S. P., Higashi, R. M., Miller, D. M., Wang, Y., Yan, J., Yuneva, M. O., Deshpande, R., Lane, A. N., and Fan, T. W. (2015) Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Invest. 125, 687-698
32. Ben-Sahra, I., Howell, J. J., Asara, J. M., and Manning, B. D. (2013) Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323-1328
33. Suzuki, A., Makinoshima, H., Wakaguri, H., Esumi, H., Sugano, S., Kohno, T., Tsuchihara, K., and Suzuki, Y. (2014) Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Res. 42, 13557-13572
34. Wang, R., and Green, D. R. (2012) Metabolic checkpoints in activated T cells. Nat. Immunol. 13, 907-915
35. Thurnher, M., and Gruenbacher, G. (2015) T lymphocyte regulation by mevalonate metabolism. Sci. Signal. 8, re4
36. Green, D. R., Galluzzi, L., and Kroemer, G. (2014) Cell biology: metabolic control of cell death. Science 345, 1250256
37. Bogan, J. S. (2012) Regulation of glucose transporter translocation in health and diabetes. Annu. Rev. Biochem. 81, 507-532
38. Watson, R. T., and Pessin, J. E. (2006) Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem. Sci. 31, 215-222
39. Leto, D., and Saltiel, A. R. (2012) Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383-396
40. Reed, B. C., Cefalu, C., Bellaire, B. H., Cardelli, J. A., Louis, T., Salamon, J., Bloecher, M. A., and Bunn, R. C. (2005) GLUT1CBP(TIP2/GIPC1) interactions with GLUT1 and myosin VI: evidence supporting an adapter function for GLUT1CBP. Mol. Biol. Cell 16, 4183-4201
41. Eyster, C. A., Higginson, J. D., Huebner, R., Porat-Shliom, N., Weigert, R., Wu, W. W., Shen, R. F., and Donaldson, J. G. (2009) Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis. Traffic 10, 590-599
42. Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., Hu, W., and Feng, Z. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935
43. Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., Shen, C. H., Wen, J., Asara, J., McGraw, T. E., Kahn, B. B., and Cantley, L. C. (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol. Cell 49, 1167-1175
44. Lee, E. E., Ma, J., Sacharidou, A., Mi, W., Salato, V. K., Nguyen, N., Jiang, Y., Pascual, J. M., North, P. E., Shaul, P. W., Mettlen, M., and Wang, R. C. (2015) A protein kinase C phosphorylation motif in GLUT1 affects glucose transport and is mutated in GLUT1 deficiency syndrome. Mol. Cell 58, 845-853
45. Tennant, D. A., Durán, R. V., and Gottlieb, E. (2010) Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267-277
46. Spratlin, J. L., Serkova, N. J., and Eckhardt, S. G. (2009) Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440
47. Kaira, K., Serizawa, M., Koh, Y., Takahashi, T., Yamaguchi, A., Hanaoka, H., Oriuchi, N., Endo, M., Ohde, Y., Nakajima, T., and Yamamoto, N. (2014) Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 83, 197-204
48. Kami, K., Fujimori, T., Sato, H., Sato, M., Yamamoto, H., Ohashi, Y., Sugiyama, N., Ishihama, Y., Onozuka, H., Ochiai, A., Esumi, H., Soga, T., and Tomita, M. (2013) Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 9, 444-453
49. Wong, K. K., Engelman, J. A., and Cantley, L. C. (2010) Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87-90
50. Busaidy, N. L., Farooki, A., Dowlati, A., Perentesis, J. P., Dancey, J. E., Doyle, L. A., Brell, J. M., and Siu, L. L. (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J. Clin. Oncol. 30, 2919-2928
51. Fruman, D. A., and Rommel, C. (2014) PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156
52. Ooi, A. T., and Gomperts, B. N. (2015) Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA. Clin. Cancer Res. 10.1158/1078-0432.CCR-14-1209